| Literature DB >> 29313009 |
Herman Hau1, Dipesh Khanal1, Linda Rogers2, Natalka Suchowerska2,3, Rajiv Kumar4, Srinivas Sridhar4, David McKenzie3,5, Wojciech Chrzanowski1,4,5,6.
Abstract
Despite major advances in the field of radiotherapy, healthy tissue damage continues to constrain the dose that can be prescribed in cancer therapy. Gold nanoparticles (GNPs) have been proposed as a solution to minimize radiation-associated toxicities by enhancing the radiation dose delivered locally to tumor cells. In the current study, we investigated the application of third-generation GNPs in two-dimensional (2D) and three-dimensional (3D) cell cultures and whether there is synergy between the nanoparticles and kilo- or mega-voltage radiation to cause augmented cytotoxicity. The 10-nm GNPs were found to be nontoxic in both 2D and 3D in vitro cultures of colon cancer cells at concentrations of up to 10-25 µg/ml. There was a significant increase in cell survival fraction reduction following exposure to 1 Gy of kilo-voltage (18.3%) and 2 Gy of mega-voltage (35.3%) radiation when the cells were incubated with 50 µg/ml of GNPs. The biocompatibility of the GNPs combined with their substantial synergy with radiation encourages further investigations into their application in targeted cancer treatment.Entities:
Keywords: colon cancer; gold nanoparticles; magnetic levitation; radiation dose enhancement; three‐dimensional cell culture
Year: 2016 PMID: 29313009 PMCID: PMC5689506 DOI: 10.1002/btm2.10007
Source DB: PubMed Journal: Bioeng Transl Med ISSN: 2380-6761
ζ‐Potential and mass median diameter of non‐PEGylated and PEGylated GNPs
| Particle type | ζ‐Potential (mV) | Size (nm) |
|---|---|---|
| Non‐PEGylated gold nanoparticles | −33.3 | 7.5 |
| PEGylated gold nanoparticles | −5.4 | 10.8 |
Figure 1Gold nanoparticles sizing by AFM and STEM. (a) Large‐scale topographic AFM image of the nGNPs fixed to mica, with a corresponding profile analysis below (scale bar = .5 µm). (b) Large‐scale topographic AFM image of the pGNP fixed to mica, with its corresponding profile analysis below (scale bar = .5 µm). (c) Small‐scale topographic AFM image of the nGNPs fixed to mica, with a corresponding profile analysis and 3D representation below (scale bar = .5 µm). (d) Small‐scale topographic AFM image of the pGNPs fixed to mica, with a corresponding profile analysis and 3D representation below (scale bar = .5 µm). (e) STEM image of the nGNPs (scale bar = 20 nm). (f) STEM image of the pGNPs (scale bar = 20 nm)
Figure 2Evaluation of pGNP toxicity in LOVO cells in 2D culture by cell growth and viability. (a) Phase images of LOVO cells treated with 0, 10, 25, and 50 µg/ml of pGNP for 7 days (scale bar = 300 µm). (b) Quantitative analysis of the confluence of LOVO cells treated with 0, 10, 25, and 50 µg/ml of pGNP over 7 days. (c) Live/Dead assay of LOVO cells treated with 0, 10, 25, and 50 µg/ml of pGNP over 7 days (scale bar = 300 µm)
Figure 3Evaluation of pGNP toxicity in LOVO cells cultured in 3D ring model. (a) Photograph of LOVO cell rings incubated with 0–100 µg/ml of pGNP at time = 0 hr (scale bar = 5 mm). (b) Photograph of LOVO cell rings incubated with 0–100 µg/ml of pGNP at time = 24 hr. (c) The contraction of the ring area over time as a percentage of its initial ring area. (d) Phase contrast images of the centre of LOVO cell rings after 24‐hr incubation with 0–100 µg/ml of pGNP (scale bar = 500 µm). Red dotted lines have been included to highlight the difference in extent of migration
Figure 4Evaluation of pGNP toxicity in LOVO cells cultured as 3D spheroids. (a) Photograph of LOVO cell spheroids incubated with 0–100 µg/ml of pGNP at time = 0 hr (scale bar = 5 mm). (b) Photograph of LOVO cell spheroids incubated with 0–100 µg/ml of pGNP at time = 24 hr. (c) The contraction of the spheroid's area over time as a percentage of its initial area. (d) Phase contrast images of the LOVO cell spheroids at time = 0 and after 24‐hr incubation with 0–100 µg/ml of pGNP (scale bar = 500 µm)
Figure 5Result of dose determination of (a) kilo‐voltage radiation, with the red highlighted dose being chosen for the study, (b) mega‐voltage radiation, with the red highlighted dose being chosen for the study, (c) GNPs concentration, with the red highlighted dose being chosen for the study. (d) The survival fraction of LOVO cells with or without incubation with 50 µg/ml of GNP and treated with kilo‐voltage or mega‐voltage radiation